Single Subcutaneous Ketamine Dose Followed by Oral Ketamine for Depression Symptoms in Hospice Patients: A Case Series

References

• Wilson KG, Chochinov HM, Graham Skirko M, Allard P, Chary S, Gagnon PR, Macmillan K, De Luca M, O'Shea F, Kuhl D, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage. 2007;33(2):118–29.
   Web of Science ®Google Scholar
• Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, et al. National Institutes of Health State-of-the-Science Conference Statement: symptom Management in Cancer: pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr. 2003;95(15):1110–7.
   Google Scholar
• Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med. 2000;132(3):310–9.
   PubMed Web of Science ®Google Scholar
• Periyakoil VS, Hallenbeck J. Identifying and managing preparatory grief and depression at the end of life. Am Fam Physician. 2002;65(5):883–90.
   PubMed Web of Science ®Google Scholar
• Noorani NH, Montagnini M. Recognizing depression in palliative care patients. J Palliat Med. 2007;10(2):458–64. doi:10.1089/jpm.2006.0099.
   PubMed Web of Science ®Google Scholar
• NHPCO Facts and Figures 2018 Edition (Revision 7-2-2019). National Hospice and Palliative Care Organization; 2019 Jul 2 [accessed 2020 Jun 1]. https://www.nhpco.org/wp-content/uploads/2019/07/2018_NHPCO_Facts_Figures.pdf.
   Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.
   Web of Science ®Google Scholar
• Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry. 2009;10(4 PART 2):640–3.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64. doi:10.1001/archpsyc.63.8.856.
   PubMed Web of Science ®Google Scholar
• Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine “burst” for refractory depression in a patient with advanced cancer. J Palliat Med. 2008;11(9):1268–71.
   PubMed Web of Science ®Google Scholar
• Krystal JH. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly. 2007;137(15–16):215–6.
   PubMed Web of Science ®Google Scholar
• McNulty JP, Hahn K. Compounded oral ketamine. Int J Pharm Compd. 2012;16(5):364–8.
   PubMedGoogle Scholar
• Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010;13(7):903–8. doi:10.1089/jpm.2010.9808.
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958–65.
   PubMed Web of Science ®Google Scholar
• Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 2012;15(4):400–3. doi:10.1089/jpm.2011.0314.
   PubMed Web of Science ®Google Scholar
• Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med. 2010;13(3):235. doi:10.1089/jpm.2009.0312.
   PubMed Web of Science ®Google Scholar
• Barbosa MG, Delfino RS, Sarin LM, Jackowski AP. Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: a case report. Palliat Med. 2020;34(6):822–5. doi:10.1177/0269216320910351.
   PubMed Web of Science ®Google Scholar
• George D, Gálvez V, Martin D, Kumar D, Leyden J, Hadzi-Pavlovic D, Harper S, Brodaty H, Glue P, Taylor R, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry. 2017;25(11):1199–209. doi:10.1016/j.jagp.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Loo CK, Gálvez V, O'Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56. doi:10.1111/acps.12572.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80:18r12475.
   PubMed Web of Science ®Google Scholar
• Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12(1):5–11. doi:10.1177/082585979601200102.
   PubMed Web of Science ®Google Scholar
• Spitzer R, Williams J, Kroenke K. Patient Health Questionnaire (PHQ) Screeners [accessed 2020 Jan 7]. https://www.phqscreeners.com/.
   Google Scholar
• Spravato (esketamine). Jannsen Pharmaceuticals, Inc. [accessed 2020 Jul 2]. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf.
   Google Scholar
• Gaynes BN, Lux L, Gartlehner G, Asher G, Forman‐Hoffman V, Green J, Boland E, Weber RP, Randolph C, Bann C, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134–45. doi:10.1002/da.22968.
   PubMed Web of Science ®Google Scholar
• Chochinov HM, Wilson KG, Enns M, Lander S. Are you depressed? Screening for depression in the terminally ill. Am J Psychiatry. 1997;154(5):674–6.
   Web of Science ®Google Scholar
• Mystakidou K, Parpa E, Tsilika E, Athanasouli P, Pathiaki M, Galanos A, Pagoropoulou A, Vlahos L. Preparatory grief, psychological distress and hopelessness in advanced cancer patients. Eur J Cancer Care. 2008;17(2):145–51. doi:10.1111/j.1365-2354.2007.00825.x.
   PubMed Web of Science ®Google Scholar
• Vergo M, Kestel J, Whyman J, Salsman J, James S. Assessing the Preparatory Grief in Advanced Cancer Patients (PGAC) instrument as an independent predictor of distress in an American population (S796). J Pain Symptom Manage. 2015;49(2):457–8.
   Web of Science ®Google Scholar
• Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852–7.
   PubMed Web of Science ®Google Scholar
• Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Therapeutic reviews ketamine*. J Pain Symptom Manage. 2011;41(3):640–9.
   PubMedGoogle Scholar
• Chaki S. Is metabolism of (R)-Ketamine essential for the antidepressant effects? Int J Neuropsychopharmacol. 2018;21(2):154–6. doi:10.1093/ijnp/pyx120.
   PubMed Web of Science ®Google Scholar